文献速递贫血与红细胞疾病

环孢素单药治疗无需输血的非重型再生障碍性贫血的疗效:一项多中心II期研究结果

Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study.
PubMed 文献 · Br J Haematol · 2025-09-08

该前瞻性II期多中心研究纳入21家机构的32例可评估的无需输血非重型再生障碍性贫血(TI-NSAA)患者,给予环孢素(CsA)3.5 mg/kg/天单药治疗,调整剂量维持给药后2小时血药浓度≥600 ng/mL。8周时红系和血小板血液学改善(HI-E、HI-P)分别为0/25(0%)和6/32(19%),52周时分别为5/25(20%)和16/32(50%)。6例患者发生9例次3级不良事件,无≥4级不良事件,10/32例发生2级肾毒性。

要点

  • CsA单药治疗TI-NSAA在52周时HI-E为20%(5/25)、HI-P为50%(16/32)。
  • 至少需16周才能充分评估CsA疗效。
  • 10/32例发生2级肾毒性,无≥4级不良事件。

核心结论

  • 低剂量CsA对TI-NSAA患者有效且肾毒性轻微,但至少需16周才能充分评估其疗效。

研究设计与样本

  • 前瞻性多中心II期研究,纳入21家机构的32例可评估的≥16岁TI-NSAA患者,接受CsA 3.5 mg/kg/天单药治疗,调整剂量维持给药后2小时血CsA水平≥600 ng/mL。

主要发现

  • 8周时HI-E为0/25(0%),HI-P为6/32(19%)。
  • 16周时HI-E为1/25(4%),HI-P为10/32(31%)。
  • 52周时HI-E为5/25(20%),HI-P为16/32(50%)。
  • 6例患者发生9例次3级不良事件,无≥4级不良事件。
  • 10/32例患者发生2级肾毒性。

关键数值与推荐

  • CsA剂量为3.5 mg/kg/天,调整维持给药后2小时血CsA水平≥600 ng/mL。
  • 血液学改善评估时间点为治疗8周、16周和52周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The efficacy of ciclosporin (CsA) to treat transfusion-independent non-severe aplastic anaemia (TI-NSAA) has not yet been systematically evaluated. We conducted a prospective trial in patients with TI-NSAA treated with CsA monotherapy. CsA (3.5 mg/kg/day) was administered to patients with TI-NSAA aged ≥16. The CsA dose was adjusted to maintain a blood CsA level of ≥600 ng/mL at 2 h post-administration. Blood cell counts were assessed after 8, 16 and 52 weeks of therapy. Thirty-two evaluable patients from 21 institutions were enrolled. The median age was 63.5 (range: 16-83) years. At 8 weeks, haematological improvement, with increases in haemoglobin (Hb) ≥1.5 g/dL (haematological improvement in erythrocytes [HI-E]) and platelet count ≥30 × 109/L (haematological improvement in platelets [HI-P]), was observed in 0/25 (0%) and 6/32 (19%) evaluable cases respectively. HI-E and HI-P occurred in 1/25 (4%) and 10/32 (31%) patients at 16 weeks, respectively, and at 52 weeks in 5/25 (20%) and 16/32 (50%) patients respectively. Nine grade 3 adverse events (AEs) occurred in six patients, but there were no grade ≥4 AEs. Ten of the 32 patients experienced grade 2 renal toxicity. Low-dose CsA is effective in TI-NSAA patients and demonstrates minimal renal toxicity. However, at least 16 weeks are necessary to adequately evaluate its efficacy.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ishiyama K, Yamazaki M, Maruyama H, et al. Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study. Br J Haematol. 2025. PMID: 40921497. doi:10.1111/bjh.70144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。